Clovis Oncology Inc. (NASDAQ:CLVS) had its price target hoisted by Stifel Nicolaus from $30.00 to $45.00 in a research note published on Wednesday. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently issued reports on the stock. SunTrust Banks Inc. started coverage on shares of Clovis Oncology in a research note on Friday, August 5th. They issued a buy rating and a $25.00 price objective for the company. Piper Jaffray Cos. set a $14.00 target price on shares of Clovis Oncology and gave the stock a hold rating in a research report on Thursday, August 18th. Vetr upgraded shares of Clovis Oncology from a buy rating to a strong-buy rating and set a $17.71 target price for the company in a research report on Thursday, June 9th. Zacks Investment Research upgraded shares of Clovis Oncology from a hold rating to a buy rating and set a $18.00 target price for the company in a research report on Thursday, August 11th. Finally, Credit Suisse Group AG restated a hold rating on shares of Clovis Oncology in a research report on Tuesday, July 12th. Six investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Clovis Oncology presently has an average rating of Buy and an average price target of $34.06.
Shares of Clovis Oncology (NASDAQ:CLVS) opened at 36.82 on Wednesday. Clovis Oncology has a 12-month low of $11.57 and a 12-month high of $109.18. The stock’s 50 day moving average is $24.67 and its 200-day moving average is $17.64. The company’s market capitalization is $1.42 billion.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($2.13) by $0.06. During the same quarter in the previous year, the firm earned ($2.10) earnings per share. Analysts anticipate that Clovis Oncology will post ($9.32) earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in CLVS. Fox Run Management L.L.C. purchased a new stake in Clovis Oncology during the second quarter valued at about $154,000. Schonfeld Strategic Advisors LLC purchased a new stake in Clovis Oncology during the first quarter valued at about $233,000. Bellevue Group AG purchased a new stake in Clovis Oncology during the first quarter valued at about $1,008,000. A.R.T. Advisors LLC raised its stake in Clovis Oncology by 148.7% in the first quarter. A.R.T. Advisors LLC now owns 283,124 shares of the biopharmaceutical company’s stock valued at $5,435,000 after buying an additional 169,273 shares during the period. Finally, Legal & General Group Plc raised its stake in Clovis Oncology by 56.8% in the first quarter. Legal & General Group Plc now owns 8,483 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 3,072 shares during the period. Hedge funds and other institutional investors own 98.46% of the company’s stock.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.